Zinc May Reverse Pulmonary Fibrosis
Zinc, a common mineral, may reverse lung damage and improve survival for patients with idiopathic pulmonary fibrosis (IPF), according to researchers from the Women’s Guild Lung Institute at Cedars-Sinai.
Category: Pulmonary Fibrosis
Pulmonary Fibrosis
Latest
Pulmonary Fibrosis
Latest
Microgel Coating Gives Donor Cells a Boost in Reversing Pulmonary Fibrosis
Research shows it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.
Pulmonary Fibrosis
Latest
Lung Fibrosis Therapies Being Developed by Purdue
The first of the Purdue team’s novel targeted molecules is designed to slow fibrosis and extend life. The second IPF therapy suppresses fibrosis-inducing cytokine production.
IPF: Stem Cells from Placental Amniotic Membrane Slow Lung Scarring
Stem cells collected from human amniotic membrane (one of the two fetal membranes forming the amniotic sac) can slow the progression of scarring in pulmonary fibrosis.
Read More
First Genomic Monitoring Test for IPF
An agreement with Yale gives Veracyte rights to a 52-gene signature developed for predicting disease progression in idiopathic pulmonary fibrosis patients.
Read More
Study Sheds Light on Key Pulmonary Fibrosis Disease Mechanisms
Researchers have elucidated the novel disease processes involved in the development of pulmonary fibrosis, according to a study published in Nature Communications.
Read More
PFF Summit Awards Highlight Pulmonary Fibrosis Research
The Pulmonary Fibrosis Foundation’s recent PFF Summit has announced winners for its poster sessions.
Read More
Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis: Causes, Diagnosis, and Treatment
Pulmonary fibrosis (PF) is a complex interstitial lung disease that afflicts an estimated 100,000 Americans, with 30-40,000 new cases diagnosed each year.
Read More
Pamrevlumab Reduced Lung Function Decline in IPF
According to research in The Lancet Respiratory Medicine, investigational antibody pamrevlumab reduced lung function decline and slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).
Read More
Pulmonary Fibrosis Drug Development Pipeline Launched
The PF Foundation has launched a new PF Drug Development Pipeline tool to help the pulmonary fibrosis community search for different treatment options.
Read More
Idiopathic Pulmonary Fibrosis Drugs Increase Longevity, Decrease Hospitalizations
Pulmonary fibrosis drugs pirfenidone and nintedanib appear to increase longevity and decrease hospitalizations in IPF patients.
Read More
Occupational Hazards Account for More Than One in Ten People with Range of Lung Diseases
More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of...
Read More
PFF Patient Registry Research Generates 23 Studies
To date, 23 studies, including abstracts and manuscripts, have been developed or are underway using data from the Pulmonary Fibrosis Foundation Patient Registry.
Read More
Drug Reduced FVC Decline in Pulmonary Fibrosis Patients
A clinical study of patients with idiopathic pulmonary fibrosis treated with PRM-151 demonstrated the drug had a sustained benefit on 6-minute walking distance and on reducing FVC decline.
Read More
Trial to Test Therapy for Persistent Cough in Pulmonary Fibrosis
Respivant Sciences has dosed the first patient in the SCENIC trial, a Phase 2b study of RVT-1601 for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).
Read More